ACIP votes to expand recommendation for RSV vaccine Abrysvo, to include adults aged 50 to 59 at increased risk of disease – Pfizer
Pfizer Inc. announced that the U.S. Centers for Disease Control and Prevention’s (CDC) Advisory Committee on Immunization Practices (ACIP) voted to expand its recommendation for the use of… read more.
